EGFR and schizophrenia: The treatment of schizophrenia may influence key proteins such as signal transducer and activator of transcription 3, TP53, and EGFR, intervening in lipid and atherosclerotic pathways, hepatitis B virus-related pathways, AGE-RAGE signaling pathways, chemical carcinogenesis receptor activation, and prostate cancer signaling pathways.